Literature DB >> 29469932

High control rates of proton- and carbon-ion-beam treatment with intensity-modulated active raster scanning in 101 patients with skull base chondrosarcoma at the Heidelberg Ion Beam Therapy Center.

Matthias Mattke1,2, Kira Vogt1,2, Nina Bougatf1,2,3,4, Thomas Welzel1,2, Jan Oelmann-Avendano1,2, Henrik Hauswald1,2,3,4, Alexandra Jensen5, Malte Ellerbrock2,3, Oliver Jäkel1,2,3,4, Thomas Haberer2,3, Klaus Herfarth1,2,3, Jürgen Debus1,2,3,4, Matthias Uhl1,2,3.   

Abstract

BACKGROUND: The current study compares the results of irradiation with protons and irradiation with carbon ions via a raster scan technique in patients with G1 and G2 skull base chondrosarcomas.
METHODS: Between 2009 and 2014, a total of 101 patients (40 men and 61 women) with a median age of 44 years (range, 19-77 years) were irradiated with carbon ions (79 patients) or protons (22 patients) via a raster scan technique at the Heidelberg Ion Beam Therapy Center. The median total dose was 60 Gy (relative biological effectiveness [RBE]) at 3 Gy per fraction for carbon ions and 70 Gy (RBE) at 2 Gy per fraction for protons. The median boost planning target volume was 38 cm3 (range, 8-133 cm3 ). Overall survival (OS) and local control (LC) were evaluated with the Kaplan-Meier method.
RESULTS: The median follow-up period was 40 months (range, 0.8-78.1 months). At the start of the irradiation, all patients had residual macroscopic tumors. Five patients (5%) developed a local recurrence during the follow-up. The 1-, 2-, and 4-year LC rates were 100%, 100%, and 100%, respectively, for protons and 98.6%, 97.2%, and 90.5%, respectively, for carbon ions. The OS rates during the same periods of time were 100%, 100%, and 100%, respectively, for protons and 100%, 98.5%, and 92.9%, respectively, for carbon ions. An age ≤ 44 years was associated with a trend for a better outcome. No toxicity worse than Common Toxicity Criteria grade 3 was observed after treatment.
CONCLUSIONS: No significant difference between carbon ions and protons in the therapy of skull base chondrosarcoma could be detected in these initial retrospective results. Cancer 2018;124:2036-44.
© 2018 American Cancer Society. © 2018 American Cancer Society.

Entities:  

Keywords:  carbon ion; chondrosarcoma; heavy ion; proton; radiotherapy; skull base

Mesh:

Substances:

Year:  2018        PMID: 29469932     DOI: 10.1002/cncr.31298

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Re-irradiation with protons or heavy ions with focus on head and neck, skull base and brain malignancies.

Authors:  Katharina Seidensaal; Semi Ben Harrabi; Matthias Uhl; Juergen Debus
Journal:  Br J Radiol       Date:  2019-11-12       Impact factor: 3.039

Review 2.  Physical advantages of particles: protons and light ions.

Authors:  Oliver Jäkel
Journal:  Br J Radiol       Date:  2019-09-26       Impact factor: 3.039

Review 3.  Particle therapy in the future of precision therapy.

Authors:  Lukas Schaub; Semi Ben Harrabi; Juergen Debus
Journal:  Br J Radiol       Date:  2020-08-14       Impact factor: 3.629

Review 4.  Clinical trials involving carbon-ion radiation therapy and the path forward.

Authors:  Ann A Lazar; Reinhard Schulte; Bruce Faddegon; Eleanor A Blakely; Mack Roach
Journal:  Cancer       Date:  2018-10-11       Impact factor: 6.860

Review 5.  Radiation therapy strategies for skull-base malignancies.

Authors:  J D Palmer; M E Gamez; K Ranta; H Ruiz-Garcia; J L Peterson; D M Blakaj; D Prevedello; R Carrau; A Mahajan; K L Chaichana; D M Trifiletti
Journal:  J Neurooncol       Date:  2020-08-12       Impact factor: 4.130

6.  Physics and biomedical challenges of cancer therapy with accelerated heavy ions.

Authors:  Marco Durante; Jürgen Debus; Jay S Loeffler
Journal:  Nat Rev Phys       Date:  2021-09-17

7.  Differential response of esophageal cancer cells to particle irradiation.

Authors:  Sarah Hartfiel; Matthias Häfner; Ramon Lopez Perez; Alexander Rühle; Thuy Trinh; Jürgen Debus; Peter E Huber; Nils H Nicolay
Journal:  Radiat Oncol       Date:  2019-07-08       Impact factor: 4.309

8.  DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.

Authors:  Rui-Xue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-05-01

9.  Application of Carbon Ion and Its Sensitizing Agent in Cancer Therapy: A Systematic Review.

Authors:  Xiaolin Wang; Xiaojun Chen; Guangfei Li; Xiao Han; Tianxin Gao; Weifeng Liu; Xiaoying Tang
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.